
Sofinnova Partners leads €16.5m series-A round for Lysogene
Sofinnova Partners has led a €16.5m series-A round for Lysogene, a biotechnology company that specialises in intracerebral therapy for the treatment of neuro-degenerative diseases.
The capital will be used to expand clinical trials for Lysogene's treatment for the currently untreatable sanfilippo syndrome. The debilitating disorder is fatal in childhood and affects one in 100,000 births.
Novo Seeds and BPI France's Innobio fund contributed to the round, which will also fund the development of a second Lysogene product targeting deficiencies in the central nervous system.
Sofinnova stated it was attracted to Lysogene given the company's progress over the past five years and by its product's potential for tackling a condition that currently has no treatment options. It had already been involved in seed funding rounds for the biotechnology company.
The VC recently joined a $10m round for portfolio company OpenERP, a Belgian open-source software company, alongside XAnge, SRIW and the management team.
Company
Founded in 2009 and based in Paris, Lysogene is a biotechnology company that focuses on the treatment of neuro-degenerative diseases. Its single dose treatment for the sanfilippo syndrome involves the injection of a functional version of the defective gene, providing the central nervous system with therapeutic protein.
People
Karen Aiach is the CEO and co-founder of Lysogene. Olivier Danos is the company's scientific adviser and co-founder. Rafaèle Tordjman, a managing partner at Sofinnova, will take a seat on the board. Henrijette Richter is an investment director at Novo and will also take a seat on the board.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater